Edition:
United States

Pluristem Therapeutics Inc (PSTI.A)

PSTI.A on American Stock Exchange

1.18USD
17 Aug 2017
Change (% chg)

-- (--)
Prev Close
$1.18
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$1.22
52-wk Low
$1.09

Latest Key Developments (Source: Significant Developments)

U.S. DOD to conduct studies of Pluristem’s PLX-R18 in a new ARS project
Wednesday, 16 Aug 2017 07:30am EDT 

Aug 16 (Reuters) - Pluristem Therapeutics Inc :U.S. Department of Defense to conduct studies of Pluristem’s PLX-R18 in a new ars project for use before radiation exposure.Pluristem Therapeutics Inc - DOD studies seek to test effectiveness of PLX-R18 as a novel medical countermeasure for acute radiation syndrome.Pluristem Therapeutics Inc - DOD studies will be conducted in parallel with ongoing ARS project with nih.  Full Article

Pluristem advances its limb ischemia study, targeting initiation at 40 active sites by the year end
Monday, 10 Jul 2017 07:00am EDT 

July 10 (Reuters) - Pluristem Therapeutics Inc :Pluristem advances its multinational phase III critical limb ischemia study, targeting initiation at 40 active sites by the end of 2017.‍Austria's regulatory health agency clears CLI study and joins U.S., U.K., and Germany in conducting 250-patient phase III trial​.‍Phase III CLI trial has received an $8 million grant from European Union's horizon 2020 program​.  Full Article

Pluristem Therapeutics says on July 7, co entered into an at market issuance sales agreement - SEC Filing
Friday, 7 Jul 2017 08:40am EDT 

July 7 (Reuters) - Pluristem Therapeutics Inc :Pluristem Therapeutics Inc - On July 7, 2017, co entered into an at market issuance sales agreement - SEC Filing.Pluristem Therapeutics Inc - Pluristem may issue and sell shares of common stock having aggregate offering price of up to $80 million from time to time.  Full Article

Pluristem Therapeutics files for mixed shelf of up to $200 mln - SEC Filing
Friday, 23 Jun 2017 09:24am EDT 

June 23 (Reuters) - Pluristem Therapeutics Inc :Pluristem Therapeutics Inc files for mixed shelf of up to $200 million - SEC Filing.  Full Article

Pluristem Therapeutics says Yaky Yanay appointed co-CEO
Friday, 23 Jun 2017 08:14am EDT 

June 23 (Reuters) - Pluristem Therapeutics Inc :Says Yaky Yanay appointed co-CEO.  Full Article

Pluristem provides results from acute radiation syndrome preclinical study
Wednesday, 3 May 2017 07:00am EDT 

May 3 (Reuters) - Pluristem Therapeutics Inc :Pluristem therapeutics inc- announces promising results from non-human primate pilot study of plx-r18 in acute radiation syndrome.Pluristem-Plx-R18 cells did not increase leukocyte levels in non-irradiated nhps; all plx-treated groups showed improvements in survival rates versus untreated groups.Pluristem therapeutics inc- data will inform a pivotal trial that could support marketing authorization under fda's animal rule regulatory pathway.  Full Article

Pluristem appoints Erez Egozi as CFO
Wednesday, 29 Mar 2017 04:00pm EDT 

Pluristem Therapeutics Inc : Pluristem launches co-CEO structure and appoints new CFO . Pluristem Therapeutics Inc - Erez Egozi appointed as chief financial officer . Pluristem Therapeutics Inc - Yaky Yanay appointed co-chief executive officer to serve together with co-chief executive officer Zami Aberman .Pluristem Therapeutics Inc - Erez Egozi appointed as chief financial officer.  Full Article

Pluristem announces bought deal offering
Thursday, 19 Jan 2017 04:53pm EST 

Pluristem Therapeutics Inc : Pluristem announces bought deal offering . Pluristem Therapeutics Inc says to sell 8.2 million shares of common stock of company, at a price to public of US$1.225 per share .Pluristem Therapeutics - Use proceeds of offering for research, product development activities, clinical trial activities, investment in capital equipment.  Full Article

Pluristem completes patient enrollment in phase II trial in intermittent claudication
Thursday, 12 Jan 2017 06:00am EST 

Pluristem Therapeutics Inc : Pluristem completes patient enrollment in a large multinational phase II trial in intermittent claudication . Expect to report top line results in early 2018 for phase II IC trial .Pluristem's IC trial is evaluating safety and efficacy of PLX-PAD cells as compared to placebo.  Full Article

U.S. FDA clears Pluristem's Phase III study of PLX-PAD cells for treatment of critical limb ischemia
Tuesday, 10 Jan 2017 07:00am EST 

Pluristem Therapeutics Inc : Pluristem's Phase III study of PLX-PAD cells for the treatment of critical limb ischemia cleared by U.S. FDA .Pluristem expects to begin enrolling patients in its Phase III study in both U.S. and Europe during first half of 2017.  Full Article

BRIEF-U.S. DOD to conduct studies of Pluristem’s PLX-R18 in a new ARS project

* U.S. Department of Defense to conduct studies of Pluristem’s PLX-R18 in a new ars project for use before radiation exposure